Medical Hashish In Canada: How One Well being Strategist Moved From Scientific Trial Registration To Hashish – And Why He is Wanting To Enhance Our Understanding Of The Remedy Class

Article content continued

Recent survey results I conducted of medical cannabis patients in Canada reported persistent barriers to legal medical regimen, including high prices, stigma from health professionals, and more. It’s no wonder the CCS 2020 reports that just over 20 percent of medical cannabis patients in Canada access treatment with a medical record from a doctor.

As many stakeholders and the industry prepare for this year’s monumental review of the Cannabis Act that governs recreational and medicinal cannabis, rumors have raged in the industry that the entire medical program could be folded if, in a few cases, there is a special review provides years.

From my point of view this is worrying. Many patients suffer from chronic and serious illnesses, multiple comorbidities and other medications. If they are further pressured to conduct their treatment outside of medical channels, they can be put at risk.

To better understand what the future of medical cannabis should be in Canada, we need to take a step back and take a holistic look at what it looks like now.

While many in the industry, including myself, frequently use “medical cannabis patients” as a collective term for the patient community, it is a heterogeneous group that spans and navigates conditions across gender, age, socio-economic status, race, sexuality, and ability ranging from anxiety and insomnia to chronic pain, multiple sclerosis, epilepsy, and much more.

Comments are closed.